NeuroDerm (NDRM) Posts Stronger Q1 Profit
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
NeuroDerm Announces First Quarter 2015 Financial Results and Provides Corporate Update
May 27, 2015 7:00 AM EDTREHOVOT, Israel, May 27, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the first quarter ended March 31, 2015 and provided a corporate update.
"We look forward to the start of our next clinical trial, a head-to-head pilot pharmacokinetic study comparing ND0612H, our subcutaneously delivered high dose product candidate for advanced Parkinson's disease, with Duodopa®, an intraduodenally-delivered product requiring surgery. Pending the study's outcome, we plan to conduct a definitive pharmacokinetic similarity study of... More
NeuroDerm Announces First Quarter 2015 Financial Results and Provides Corporate Update
May 27, 2015 7:00 AM EDTREHOVOT, Israel, May 27, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the first quarter ended March 31, 2015 and provided a corporate update.
"We look forward to the start of our next clinical trial, a head-to-head pilot pharmacokinetic study comparing ND0612H, our subcutaneously delivered high dose product candidate for advanced Parkinson's disease, with Duodopa®, an intraduodenally-delivered product requiring surgery. Pending the study's outcome, we plan to conduct a definitive pharmacokinetic similarity study of... More
